Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6287491 | 0.88 | CLK1 (0.47) | RXFP1SMN1; SMN2MAPTHPGDKDM4E | |
| SCHEMBL6288966 | 0.82 | RXFP1 (0.51) | RXFP1SMN1; SMN2HPGDCYP1A2CYP2C9 | |
| SCHEMBL6737035 | 0.82 | RXFP1 (0.46) | RXFP1SMN1; SMN2MAPTHPGDKDM4E | |
| SCHEMBL6287426 | 0.81 | MEN1 (0.43) | MAPTHPGDALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL6285943 | 0.80 | RXFP1 (0.46) | RXFP1SMN1; SMN2MAPTHPGDKDM4E | |
| SCHEMBL6286356 | 0.79 | RXFP1 (0.59) | RXFP1ALDH1A1TSHR | |
| SCHEMBL6283698 | 0.79 | RXFP1 (0.54) | RXFP1SMN1; SMN2MAPTHPGDKDM4E | |
| SCHEMBL6283710 | 0.78 | RXFP1 (0.50) | RXFP1SMN1; SMN2HPGDCYP1A2CYP2C9 | |
| SCHEMBL6279640 | 0.77 | CYP1A2 (0.44) | SMN1; SMN2HPGDKDM4ETSHRCYP1A2 | |
| SCHEMBL6288995 | 0.74 | GAA (0.41) | MAPTHPGDCYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176366-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-09-09 | — | — | US | claimed |
| US-20040142928-A1 | Heterocycle carboxamides as antiviral agents | BUNDY GORDON L (US) | 2004-07-22 | — | — | US | claimed |
| US-20030207880-A1 | Heterocycle carboxamides as antiviral agents | BUNDY GORDON L (US) | 2003-11-06 | — | — | US | claimed |
| US-20020025960-A1 | Heterocycle carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-02-28 | — | — | US | claimed |
| US-6903097-B2 | Heterocycle carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY (US) | 2005-06-07 | — | — | US | disclosed |
| US-20040176366-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-09-09 | — | — | US | disclosed |
| US-20040142928-A1 | Heterocycle carboxamides as antiviral agents | BUNDY GORDON L (US) | 2004-07-22 | — | — | US | disclosed |
| US-20030207880-A1 | Heterocycle carboxamides as antiviral agents | BUNDY GORDON L (US) | 2003-11-06 | — | — | US | disclosed |
| US-6559145-B2 | Herpes virus | PHARMACIA & UPJOHN COMPANY | 2003-05-06 | — | — | US | disclosed |
| US-20020025960-A1 | Heterocycle carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176366-A1 | Method of preventing or treating atherosclerosis or restenosis | LDLR, NR1H3, NR1H2 | RXFP1 47/4885SMN1; SMN2 3519/4885MAPT 4880/4885 |
| US-20040142928-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | RXFP1 3897/4885SMN1; SMN2 4321/4885MAPT 4388/4885 |
| US-20020025960-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | RXFP1 3897/4885SMN1; SMN2 4321/4885MAPT 4388/4885 |
| US-20030207880-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | RXFP1 3897/4885SMN1; SMN2 4321/4885MAPT 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.